PKD2 (Polycystin-2) variants and mutations
PKD2 (also known as Polycystin-2) is a human protein-coding gene encoding a polycystin-2 protein. It provides calcium-permeable polycystin channel activity and forms signaling complexes with polycystin-1 in renal epithelial cells. Loss-of-function variants cause autosomal dominant polycystic kidney disease, generally with a milder average course than PKD1-associated disease. This analysis covers 1,679 PKD2 variants and mutations. Of these, 83% have computational variant effect predictions. Disease context includes polycystic kidney disease 2, autosomal dominant polycystic kidney disease, and cystic kidney disease. Example PKD2 variants include M1K, V2M, and V2L.
Variant analysis overview
- Gene: PKD2
- Protein: Polycystin-2
- UniProt accession: Q13563
- Organism: Homo sapiens
- Variants analyzed: 1679
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 1,227 unspecified-consequence records; 275 missense variants; 106 synonymous variants; 39 frameshift variants; 20 stop-gained variants; 10 in-frame deletions; 1 in-frame insertions; 1 substitution
- Prediction scores: 1,400 variants have prediction scores (83% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: polycystic kidney disease 2, autosomal dominant polycystic kidney disease, cystic kidney disease, polycystic kidney disease, chronic kidney disease, kidney disorder, Genetic renal or urinary tract malformation, urinary system disorder, Abnormality of the urinary system, Meckel syndrome, kidney failure, Abnormality of the liver.
Protein structure and variant hotspots
- Protein features: 6 transmembrane segments; 1 domains; 7 binding sites; 12 post-translational modification sites.
- Structural context: 184 variants have structural context.
- PTM context: 19 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable PKD2 variants
Examples include M1K, V2M, V2L, V2A, V2E, V2V, N3D, N3S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1K (p.Met1Lys), rs1477510994, ClinGen CA357624744, ClinVar RCV002988662, ClinVar RCV004774769, MetaLR 0.15, MetaSVM -0.77, Uncertain significance, Autosomal dominant polycystic kidney disease; not provided
- V2M (p.Val2Met), TOPMed rs1726221508, REVEL 0.07, CADD 15.70
- V2L (p.Val2Leu), gnomAD 4-88007737-G-C, REVEL 0.13, CADD 20.00
- V2A (p.Val2Ala), gnomAD 4-88007738-T-C, REVEL 0.10, CADD 21.10
- V2E (p.Val2Glu), gnomAD 4-88007738-T-A, REVEL 0.13, CADD 21.90
- V2V (p.Val2Val), gnomAD 4-88007739-G-C, CADD 7.52
- N3D (p.Asn3Asp), gnomAD 4-88007740-A-G, REVEL 0.05, CADD 21.00
- N3S (p.Asn3Ser), gnomAD 4-88007741-A-G, REVEL 0.06, CADD 15.60
- N3I (p.Asn3Ile), gnomAD 4-88007741-A-T, REVEL 0.03, CADD 21.70
- N3N (p.Asn3Asn), rs773343245, gnomAD 4-88007742-C-T, CADD 10.60
- N3K (p.Asn3Lys), gnomAD 4-88007742-C-A, REVEL 0.10, CADD 21.20
- S4Y (p.Ser4Tyr), rs1726221678, ClinGen CA357624790, ClinVar RCV002508657, TOPMed rs1726221678, REVEL 0.06, CADD 20.40, Uncertain significance, not provided
- S4P (p.Ser4Pro), gnomAD 4-88007743-T-C, REVEL 0.09, CADD 18.30
- S4F (p.Ser4Phe), gnomAD 4-88007744-C-T, REVEL 0.05, CADD 21.50
- S4C (p.Ser4Cys), gnomAD 4-88007744-C-G, REVEL 0.06, CADD 20.90
- S4S (p.Ser4Ser), rs1391499589, gnomAD 4-88007745-C-T, CADD 8.32
- S5V (p.Ser5Val), gnomAD 4-88007743-TC-T, CADD 22.70
- S5G (p.Ser5Gly), gnomAD 4-88007746-A-G, REVEL 0.18, CADD 20.80
- S5R (p.Ser5Arg), gnomAD 4-88007746-A-C, REVEL 0.13, CADD 17.30
- S5C (p.Ser5Cys), gnomAD 4-88007746-A-T, REVEL 0.08, CADD 21.70
- S5I (p.Ser5Ile), gnomAD 4-88007747-G-T, REVEL 0.05, CADD 18.70
- S5N (p.Ser5Asn), gnomAD 4-88007747-G-A, REVEL 0.22, CADD 17.10
- S5T (p.Ser5Thr), gnomAD 4-88007747-G-C, REVEL 0.07, CADD 13.00
- S5S (p.Ser5Ser), rs760925232, gnomAD 4-88007748-T-C, CADD 8.21
- R6H (p.Arg6His), rs1307960365, ClinGen CA357624804, ClinVar RCV002907688, TOPMed rs1307960365, REVEL 0.11, CADD 22.90, Uncertain significance, Autosomal dominant polycystic kidney disease
- R6L (p.Arg6Leu), TOPMed rs1307960365, gnomAD rs1307960365, REVEL 0.11, CADD 22.80, Uncertain significance, Polycystic kidney disease 2
- R6C (p.Arg6Cys), gnomAD 4-88007749-C-T, REVEL 0.21, CADD 23.10
- R6S (p.Arg6Ser), gnomAD 4-88007749-C-A, REVEL 0.05, CADD 22.20
- R6G (p.Arg6Gly), gnomAD 4-88007749-C-G, REVEL 0.08, CADD 22.40
- R6P (p.Arg6Pro), gnomAD 4-88007750-G-C, REVEL 0.17, CADD 23.10
- R6R (p.Arg6Arg), gnomAD 4-88007751-C-G, CADD 11.40
- V7M (p.Val7Met), rs1366782791, ClinGen CA357624807, ClinVar RCV001367775, ClinVar RCV003298597, REVEL 0.10, CADD 22.50, Uncertain significance, Autosomal dominant polycystic kidney disease; Inborn genetic diseases
- V7L (p.Val7Leu), gnomAD 4-88007752-G-T, REVEL 0.07, CADD 22.00
- V7A (p.Val7Ala), gnomAD 4-88007753-T-C, REVEL 0.12, CADD 22.90
- V7G (p.Val7Gly), gnomAD 4-88007753-T-G, REVEL 0.10, CADD 23.00
- V7V (p.Val7Val), rs1242420595, gnomAD 4-88007754-G-C, CADD 10.80
- Q8* (p.Gln8Ter), ExAC rs766216683, gnomAD rs766216683, CADD 36.00
- Q8R (p.Gln8Arg), rs2110080023, ClinGen CA357624815, ClinVar RCV001958063, Ensembl rs2110080023, REVEL 0.10, CADD 16.40, Uncertain significance, Autosomal dominant polycystic kidney disease
- Q8K (p.Gln8Lys), gnomAD 4-88007755-C-A, REVEL 0.09, CADD 16.60
- Q8E (p.Gln8Glu), gnomAD 4-88007755-C-G, REVEL 0.15, CADD 20.00
- Q8H (p.Gln8His), gnomAD 4-88007757-G-C, REVEL 0.10, CADD 22.80
- Q8Q (p.Gln8Gln), gnomAD 4-88007757-G-A, CADD 11.50
- P9L (p.Pro9Leu), rs1392093609, Ensembl rs1392093609, REVEL 0.19, CADD 24.90, Variant assessed as somatic; moderate impact.
- P9S (p.Pro9Ser), gnomAD rs1322007122, REVEL 0.18, CADD 23.80
- P9T (p.Pro9Thr), gnomAD 4-88007758-C-A, REVEL 0.20, CADD 23.70
- P9H (p.Pro9His), gnomAD 4-88007759-C-A, REVEL 0.23, CADD 24.60
- P9R (p.Pro9Arg), gnomAD 4-88007759-C-G, REVEL 0.20, CADD 24.60
- P9P (p.Pro9Pro), gnomAD 4-88007760-T-C, CADD 14.30
- Q10S (p.Gln10Ser), gnomAD 4-88007759-CT-C, CADD 23.00
- Q10* (p.Gln10Ter), gnomAD 4-88007761-C-T, CADD 36.00
- Q10K (p.Gln10Lys), gnomAD 4-88007761-C-A, REVEL 0.08, CADD 22.70
- Q10E (p.Gln10Glu), gnomAD 4-88007761-C-G, REVEL 0.09, CADD 22.40
- Q10R (p.Gln10Arg), gnomAD 4-88007762-A-G, REVEL 0.09, CADD 23.00
- Q10L (p.Gln10Leu), gnomAD 4-88007762-A-T, REVEL 0.07, CADD 23.40
- Q10H (p.Gln10His), gnomAD 4-88007763-G-C, REVEL 0.12, CADD 23.00
- Q10Q (p.Gln10Gln), gnomAD 4-88007763-G-A, CADD 12.00
- Q11H (p.Gln11His), Ensembl rs1726222567, REVEL 0.04, CADD 21.10
- Q11P (p.Gln11Pro), Ensembl rs1726222485
- Q11S (p.Gln11Ser), gnomAD 4-88007763-GC-G, CADD 23.20
- Q11* (p.Gln11Ter), gnomAD 4-88007764-C-T, CADD 36.00
- Q11E (p.Gln11Glu), gnomAD 4-88007764-C-G, REVEL 0.11, CADD 15.40
- Q11K (p.Gln11Lys), gnomAD 4-88007764-C-A, REVEL 0.07, CADD 15.90
- Q11R (p.Gln11Arg), gnomAD 4-88007765-A-G, REVEL 0.07, CADD 11.90
- Q11Q (p.Gln11Gln), gnomAD 4-88007766-G-A, CADD 10.70
- P12A (p.Pro12Ala), TOPMed rs1726222650, REVEL 0.09, CADD 21.40
- P12L (p.Pro12Leu), rs1459980217, ClinGen CA357624872, ClinVar RCV003747681, TOPMed rs1459980217, REVEL 0.09, CADD 22.80, Likely benign, Autosomal dominant polycystic kidney disease
- P12R (p.Pro12Arg), TOPMed rs1459980217, gnomAD rs1459980217, REVEL 0.13, CADD 22.90, Likely benign
- P12T (p.Pro12Thr), gnomAD 4-88007767-C-A, REVEL 0.11, CADD 22.10
- P12S (p.Pro12Ser), gnomAD 4-88007767-C-T, REVEL 0.11, CADD 18.80
- P12H (p.Pro12His), gnomAD 4-88007768-C-A, REVEL 0.15, CADD 24.00
- P12P (p.Pro12Pro), gnomAD 4-88007769-C-A, CADD 13.20
- G13E (p.Gly13Glu), TOPMed rs1415908750, gnomAD rs1415908750, REVEL 0.09, CADD 23.10, Uncertain significance, Autosomal dominant polycystic kidney disease
- G13R (p.Gly13Arg), rs1228430587, ClinGen CA357624878, ClinVar RCV003746365, TOPMed rs1228430587, REVEL 0.05, CADD 23.60, Uncertain significance, Autosomal dominant polycystic kidney disease
- G13W (p.Gly13Trp), gnomAD 4-88007770-G-T, REVEL 0.16, CADD 27.10
- G13A (p.Gly13Ala), gnomAD 4-88007771-G-C, REVEL 0.06, CADD 19.20
- G13V (p.Gly13Val), gnomAD 4-88007771-G-T, REVEL 0.11, CADD 23.20
- G13G (p.Gly13Gly), gnomAD 4-88007772-G-T, CADD 12.90
- D14Y (p.Asp14Tyr), TOPMed rs1166035431, gnomAD rs1166035431, REVEL 0.07, CADD 24.00
- D14T (p.Asp14Thr), gnomAD 4-88007766-GC-G, CADD 23.90
- D14R (p.Asp14Arg), gnomAD 4-88007769-CGG-C, CADD 25.50
- D14G (p.Asp14Gly), gnomAD 4-88007769-C-CG, CADD 26.30
- D14N (p.Asp14Asn), gnomAD 4-88007773-G-A, REVEL 0.09, CADD 22.20
- D14A (p.Asp14Ala), rs1474473957, gnomAD 4-88007773-GA-G, CADD 22.30
- D14E (p.Asp14Glu), gnomAD 4-88007775-C-A, REVEL 0.08, CADD 14.30
- D14D (p.Asp14Asp), gnomAD 4-88007775-C-T, CADD 10.50
- A15P (p.Ala15Pro), gnomAD 4-88007776-G-C, REVEL 0.14, CADD 17.80
- A15T (p.Ala15Thr), gnomAD 4-88007776-G-A, REVEL 0.09, CADD 13.60
- A15S (p.Ala15Ser), gnomAD 4-88007776-G-T, REVEL 0.11, CADD 12.20
- A15V (p.Ala15Val), gnomAD 4-88007777-C-T, REVEL 0.17, CADD 15.40
- A15D (p.Ala15Asp), gnomAD 4-88007777-C-A, REVEL 0.07, CADD 19.50
- A15A (p.Ala15Ala), gnomAD 4-88007778-C-A, CADD 6.18
- K16E (p.Lys16Glu), rs1241520333, ClinGen CA357624920, ClinVar RCV003814971, ClinVar RCV004753723, REVEL 0.07, CADD 2.60, Uncertain significance, Autosomal dominant polycystic kidney disease
- K16R (p.Lys16Arg), TOPMed rs927151115, gnomAD rs927151115, REVEL 0.03, CADD 7.47
- K16S (p.Lys16Ser), gnomAD 4-88007776-GC-G, CADD 22.20
- K16* (p.Lys16Ter), gnomAD 4-88007779-A-T, CADD 32.00
- K16T (p.Lys16Thr), gnomAD 4-88007780-A-C, REVEL 0.03, CADD 9.87
- K16K (p.Lys16Lys), gnomAD 4-88007781-G-A, CADD 9.74
- K16N (p.Lys16Asn), gnomAD 4-88007781-G-T, REVEL 0.02, CADD 15.70
- R17L (p.Arg17Leu), TOPMed rs938764650, gnomAD rs938764650, REVEL 0.13, CADD 17.50, Uncertain significance, Inborn genetic diseases; Autosomal dominant polycystic kidney disease
- R17Q (p.Arg17Gln), TOPMed rs938764650, gnomAD rs938764650, REVEL 0.07, CADD 17.90, Uncertain significance
- R17G (p.Arg17Gly), gnomAD 4-88007769-C-CGGG, CADD 26.00
- R17A (p.Arg17Ala), gnomAD 4-88007780-AGC-A, CADD 22.30
- R17W (p.Arg17Trp), gnomAD 4-88007782-C-T, REVEL 0.12, CADD 22.20
- R17R (p.Arg17Arg), gnomAD 4-88007782-C-A, CADD 10.80
- R17P (p.Arg17Pro), gnomAD 4-88007783-G-C, REVEL 0.08, CADD 18.20
- P18Q (p.Pro18Gln), Ensembl rs1560591768, REVEL 0.05, CADD 12.20
- P18S (p.Pro18Ser), gnomAD rs1227851635, REVEL 0.07, CADD 2.40
- P18R (p.Pro18Arg), gnomAD 4-88007784-GC-G, CADD 13.70
- P18T (p.Pro18Thr), gnomAD 4-88007785-C-A, REVEL 0.12, CADD 3.25
- P18A (p.Pro18Ala), gnomAD 4-88007785-C-G, REVEL 0.10, CADD 3.38
- P18L (p.Pro18Leu), gnomAD 4-88007786-C-T, REVEL 0.06, CADD 17.70
- P18P (p.Pro18Pro), gnomAD 4-88007787-G-T, CADD 9.38
- P19L (p.Pro19Leu), rs2476356530, ClinGen CA357624959, ClinVar RCV002824897, REVEL 0.10, CADD 21.00, Uncertain significance, Autosomal dominant polycystic kidney disease
- P19S (p.Pro19Ser), rs2476356520, ClinGen CA357624957, ClinVar RCV003747170, REVEL 0.11, CADD 10.60, Uncertain significance, Autosomal dominant polycystic kidney disease
- P19T (p.Pro19Thr), gnomAD 4-88007788-C-A, REVEL 0.12, CADD 14.90
- P19H (p.Pro19His), gnomAD 4-88007789-C-A, REVEL 0.14, CADD 20.70
- P19R (p.Pro19Arg), gnomAD 4-88007789-C-G, REVEL 0.09, CADD 16.20
- P19P (p.Pro19Pro), gnomAD 4-88007790-C-T, CADD 7.93
- A20P (p.Ala20Pro), TOPMed rs1490499917, gnomAD rs1490499917, REVEL 0.04, CADD 15.60
- A20T (p.Ala20Thr), TOPMed rs1490499917, gnomAD rs1490499917, REVEL 0.05, CADD 15.80
- A20V (p.Ala20Val), rs1213258236, ClinGen CA357624971, ClinVar RCV001288350, TOPMed rs1213258236, REVEL 0.06, CADD 16.10, Uncertain significance, not provided
- A20R (p.Ala20Arg), rs1560591780, gnomAD 4-88007786-CG-C, CADD 20.70
- A20S (p.Ala20Ser), gnomAD 4-88007791-G-T, REVEL 0.04, CADD 13.80
- A20G (p.Ala20Gly), gnomAD 4-88007792-C-G, REVEL 0.07, CADD 15.20
- A20E (p.Ala20Glu), gnomAD 4-88007792-C-A, REVEL 0.02, CADD 16.10
- A20A (p.Ala20Ala), gnomAD 4-88007793-G-A, CADD 10.90
- P21S (p.Pro21Ser), TOPMed rs1265006798, gnomAD rs1265006798, REVEL 0.04, CADD 17.00, Uncertain significance, Polycystic kidney disease 2
- P21T (p.Pro21Thr), rs1265006798, TOPMed rs1265006798, gnomAD rs1265006798, REVEL 0.02, CADD 12.80, Uncertain significance
- P21A (p.Pro21Ala), gnomAD 4-88007794-C-G, REVEL 0.02, CADD 11.80
- P21R (p.Pro21Arg), gnomAD 4-88007795-C-G, REVEL 0.07, CADD 20.80
- P21L (p.Pro21Leu), gnomAD 4-88007795-C-T, REVEL 0.08, CADD 21.60
- P21H (p.Pro21His), gnomAD 4-88007795-C-A, REVEL 0.12, CADD 21.50
- P21P (p.Pro21Pro), rs2110080070, gnomAD 4-88007796-C-T, CADD 9.67
- R22C (p.Arg22Cys), TOPMed rs1338261349, gnomAD rs1338261349, REVEL 0.11, CADD 22.20, Uncertain significance
- R22H (p.Arg22His), rs1450630438, ClinGen CA357624997, ClinVar RCV002926817, ClinVar RCV004753588, REVEL 0.05, CADD 21.00, Uncertain significance, Autosomal dominant polycystic kidney disease; Polycystic kidney disease 2; Inbor
- R22L (p.Arg22Leu), TOPMed rs1450630438, gnomAD rs1450630438, REVEL 0.05, CADD 16.90, Uncertain significance, Autosomal dominant polycystic kidney disease
- R22S (p.Arg22Ser), rs1338261349, ClinGen CA357624991, ClinVar RCV002774901, ClinVar RCV004067894, REVEL 0.07, CADD 19.80, Uncertain significance, Inborn genetic diseases; Autosomal dominant polycystic kidney disease
- R22A (p.Arg22Ala), rs1211371246, gnomAD 4-88007793-GC-G, CADD 21.10
- R22G (p.Arg22Gly), gnomAD 4-88007797-C-G, REVEL 0.07, CADD 16.40
- R22P (p.Arg22Pro), gnomAD 4-88007798-G-C, REVEL 0.03, CADD 21.40
- R22R (p.Arg22Arg), rs1368294684, gnomAD 4-88007799-C-T, CADD 10.90
- A23T (p.Ala23Thr), gnomAD rs1726225217, REVEL 0.03, CADD 12.50
- A23V (p.Ala23Val), rs2110080081, ClinGen CA357625012, ClinVar RCV002771046, 1000Genomes rs2110080081, REVEL 0.08, CADD 15.40, Uncertain significance, Autosomal dominant polycystic kidney disease
- A23S (p.Ala23Ser), gnomAD 4-88007800-G-T, REVEL 0.04, CADD 10.30
- A23E (p.Ala23Glu), gnomAD 4-88007801-C-A, REVEL 0.07, CADD 12.60
- A23A (p.Ala23Ala), gnomAD 4-88007802-G-C, CADD 9.88
- P24L (p.Pro24Leu), rs1004860210, UniProt VAR 058820, TOPMed rs1004860210, gnomAD rs1004860210, REVEL 0.08, CADD 13.40
- P24S (p.Pro24Ser), rs786204221, ClinGen CA334636, ClinVar RCV002053997, ClinVar RCV003927558, REVEL 0.04, CADD 6.86, Conflicting interpretations, Autosomal dominant polycystic kidney disease; not specified
- P24G (p.Pro24Gly), gnomAD 4-88007802-GCC-G, CADD 20.30
- P24T (p.Pro24Thr), gnomAD 4-88007803-C-A, REVEL 0.03, CADD 9.91
- P24A (p.Pro24Ala), gnomAD 4-88007803-C-G, REVEL 0.07, CADD 5.60
- P24Q (p.Pro24Gln), gnomAD 4-88007804-C-A, REVEL 0.02, CADD 12.50
- P24P (p.Pro24Pro), gnomAD 4-88007805-G-A, CADD 9.74
- D25E (p.Asp25Glu), gnomAD rs1326771400, REVEL 0.07, CADD 5.57
- D25G (p.Asp25Gly), TOPMed rs1351341206, REVEL 0.04, CADD 9.42
- D25H (p.Asp25His), rs2476356623, ClinGen CA357625028, ClinVar RCV003585442, REVEL 0.08, CADD 16.10, Uncertain significance, Autosomal dominant polycystic kidney disease
- D25Y (p.Asp25Tyr), gnomAD 4-88007806-G-T, REVEL 0.05, CADD 20.20
- D25N (p.Asp25Asn), gnomAD 4-88007806-G-A, REVEL 0.03, CADD 16.40
- D25V (p.Asp25Val), gnomAD 4-88007807-A-T, REVEL 0.13, CADD 17.90
- D25D (p.Asp25Asp), gnomAD 4-88007808-C-T, CADD 6.19
- P26L (p.Pro26Leu), rs1447102982, ClinGen CA357625048, ClinVar RCV002770237, REVEL 0.13, CADD 20.20, Uncertain significance, Autosomal dominant polycystic kidney disease
- P26Q (p.Pro26Gln), gnomAD rs1447102982, REVEL 0.13, CADD 19.90
- P26S (p.Pro26Ser), rs1037715951, ClinGen CA100872988, ClinVar RCV002770096, ClinVar RCV005382473, REVEL 0.03, CADD 17.60, Uncertain significance, Inborn genetic diseases; Autosomal dominant polycystic kidney disease
- P26T (p.Pro26Thr), rs1037715951, ClinGen CA357625038, ClinVar RCV002725744, REVEL 0.03, CADD 16.90, Uncertain significance, Autosomal dominant polycystic kidney disease
- P26R (p.Pro26Arg), gnomAD 4-88007807-AC-A, CADD 14.30
- P26P (p.Pro26Pro), rs899378635, gnomAD 4-88007811-G-T, CADD 5.92
- G27C (p.Gly27Cys), gnomAD 4-88007812-G-T, REVEL 0.14, CADD 22.90
- G27S (p.Gly27Ser), gnomAD 4-88007812-G-A, REVEL 0.12, CADD 18.80
- G27V (p.Gly27Val), gnomAD 4-88007813-G-T, REVEL 0.13, CADD 23.00
- G27D (p.Gly27Asp), gnomAD 4-88007813-G-A, REVEL 0.03, MetaLR 0.12
- G27G (p.Gly27Gly), gnomAD 4-88007814-C-A, CADD 8.93
- R28P (p.Arg28Pro), rs1805044, ClinGen CA146023, ClinVar RCV000078585, ClinVar RCV000287058, REVEL 0.05, CADD 21.80, Benign, Autosomal dominant polycystic kidney disease; not specified; not provided
- R28Q (p.Arg28Gln), 1000Genomes rs1805044, ExAC rs1805044, TOPMed rs1805044, gnomAD rs1805044, REVEL 0.08, CADD 21.50, Benign
- R28W (p.Arg28Trp), rs2476356645, ClinGen CA357625069, ClinVar RCV002575037, ClinVar RCV002575038, REVEL 0.08, CADD 22.10, Uncertain significance, Inborn genetic diseases; Autosomal dominant polycystic kidney disease
- R28R (p.Arg28Arg), gnomAD 4-88007815-C-A, CADD 10.70
- R28L (p.Arg28Leu), gnomAD 4-88007816-G-T, REVEL 0.04, MetaLR 0.12
- L29V (p.Leu29Val), rs1578111148, ClinGen CA357625084, ClinVar RCV001244464, Ensembl rs1578111148, REVEL 0.02, CADD 15.10, Uncertain significance, Autosomal dominant polycystic kidney disease
- L29M (p.Leu29Met), gnomAD 4-88007818-C-A, REVEL 0.08, MetaLR 0.12
- L29L (p.Leu29Leu), gnomAD 4-88007818-C-T, CADD 10.20
- M30K (p.Met30Lys), TOPMed rs1726226212, gnomAD rs1726226212, REVEL 0.09, CADD 18.10, Uncertain significance, Polycystic kidney disease 2
Public PKD2 analysis runs
- PKD2 analysis run — PKD2 (1,679 variants) — completed 2026-08-18